Because ALDH1+ CSCs usually reside in the center of the tumor, while CD44+/CD24− cells are found at the edge, and these cell phenotypes can transition between the types, sampling bias may have affected the results before and after treatment. The gene discussed is ALDH1A1; the disease is neoplasm.